卵巢癌中的HIPEC 是未来...并且永远是吗? 来自西班牙多中心调查的结果
Alida González Gil1, Álvaro Cerezuela Fernández-de Palencia2, Álvaro Jesús Gómez Ruiz2
1Departamento de Cirugía, Unidad de Cirugía Oncológica Peritoneal, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-ARRIXACA, 30120 Murcia, Spain.
Cancers
|July 14, 2023
概括
超热性腹膜内化学疗法 (HIPEC) 对卵巢癌具有前景,但其采用速度缓慢. 大多数西班牙手术团体在关键试验后没有改变临床实践,突出了研究和现实应用之间的差距.
科学领域:
- 妇科瘤学 妇科瘤学
- 手术瘤学手术瘤学
- 临床试验研究 临床试验研究
背景情况:
- 卵巢癌仍然是妇科瘤死亡的主要原因.
- 复发是常见的,尽管标准的治疗,如细胞减少和化疗.
- 由于有限的高质量证据,高热性腹腔内化学疗法 (HIPEC) 的使用受到争议.
研究的目的:
- 评估一个关键的随机对照试验 (RCT) 对卵巢癌的HIPEC对临床实践的影响.
- 为了探索在西班牙采用HIPEC之后的HIPEC在西班牙的采用. 试验结果. 试验结果.
主要方法:
- 在西班牙腹腔外科瘤学小组 (GECOP) 中进行了一项全国性调查.
- 33个手术组对调查做出了回应,关于他们在RCT后的临床实践变化.
主要成果:
- 85%的受访组 (共33组中的28组) 没有根据范德里尔试验改变其常规的临床实践.
- 大多数团体认为,在将HIPEC视为护理标准之前,需要进行进一步的RCT.
结论:
- 对卵巢癌的HIPEC进行RCT的结果并没有转化为广泛的临床实践变化.
- 研究结果与其在常规妇科瘤治疗中的实施之间存在很大的差距.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...